Phase 1 Trials: What to Expect
Overall, it is estimated that approximately 7% to 11% of patients experience tumor shrinkage in phase 1 trials.
Overall, it is estimated that approximately 7% to 11% of patients experience tumor shrinkage in phase 1 trials.
This fact sheet reviews a large epidemiologic study about lifestyle choices, such as diet and exercise, and risk of developing prostate cancer.
This fact sheet reviews studies that evaluated a potential link between hair dye, deodorant/antiperspirant, or personal care product use and cancer.
The results of a recent ASCO poll suggest that many adults are unsure how to reduce their cancer risk and do not know what sources of information to trust.
This fact sheet provides an overview of data on dietary acrylamide and the risk of developing cancer.
This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.
This fact sheet describes the potential role of dietary flavonoids in reducing cancer risk.
This fact sheet explains biosimilars: what they are, how they differ from the original biologic, and their availability.
This fact sheet explains the processes involved in drug development and FDA drug approval.
This fact sheet provides the meaning of oncology lingo that patients may commonly hear following a cancer diagnosis.